'Peg ifn rbv' presentation slideshows

How to Optimize Treatment of non G1 Patients

Luncheons PHC Paris January 31, 2012. How to Optimize Treatment of non G1 Patients. Alessandra Mangia S. Giovanni Rotondo ITALY. March 14, 2011. 49 years old man, BMI: 28 HCV diagnosed in 1998 - previous iv drug and alcohol user - genotype 3, HCVRNA:410.000 IU/ml

621 views • 50 slides

624 views • 46 slides

HCV 2014 and b eyond the i nterferon era

HCV 2014 and b eyond the i nterferon era. Patrick M. Horne, MSN, ARNP, FNP-BC Assistant Director of Hepatology Clinical Research Division of Gastroenterology, Hepatology and Nutrition University of Florida Health. Disclosures and Off-label Discussion.

555 views • 37 slides

Standard Interferon vs. Pegylated Interferon

316 views • 30 slides

Observations from the Antiviral Information Management System (AIMS) Database

Observations from the Antiviral Information Management System (AIMS) Database. Jeffry Florian, Ph.D. CDER/OTS/OCP Division of Pharmacometrics, Reviewer

434 views • 29 slides

New Anti-HCV Drugs Other Drugs?

578 views • 27 slides

36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago

Case study. 36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 only qualitative PCR available : positive at W12 and W24 Treatment stopped after 24 weeks Weight: 65 kg, BMI: 23 No comorbidity, no medications

337 views • 23 slides